Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L31/148—Materials at least partially resorbable by the body
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/14—Macromolecular materials
  • A61L27/26—Mixtures of macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/58—Materials at least partially resorbable by the body
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/04—Macromolecular materials
  • A61L31/041—Mixtures of macromolecular compounds

Definitions

• Biodegradable polymers have found use in a wide variety of applications ranging from trash bags that decompose in landfills to implantable medical devices that biodegrade in the body. Most of these applications require that such polymers have adequate physical properties and stability to provide for suitable handling and utility prior to being subjected to end use conditions that promote biodegradation. Further, it is often preferable that these same polymers rapidly or controllably biodegrade once subjected to such end use conditions. In addition, it is often desired that biodegradable polymers used for implantable medical devices be converted under physiological conditions to materials that do not irritate or harm the surrounding tissue. Many biodegradable polymers known in the art lack the combination of physical and/or chemical properties desired to meet the needs for specific applications.
• polylactide homopolymers e.g., poly-L-lactide, PLA
• copolymers e.g., polyfL-lactide-co-glycolide; PLGA
• PLGA polyfL-lactide-co-glycolide
• Brittle polymers can sometimes be blended with polymers that are softer at the temperature of use to reduce the brittleness.
• polylactide homopolymers polylactide homopolymers
• poly-L-lactide e.g., poly-L-lactide; PLA
• copolymers e.g., poly(L-lactide-co-glycolide; PLGA
• PTMC poly(trimethylene carbonate)
• PCL poLycaprolactone
• PCL polyhydroxybutyrate
• the present disclosure provides polymer blends and methods of making and using polymer blends that can have properties suitable for use in medical devices
• the present disclosure provides an implantable medical device that includes a polymer blend
• the polymer blend includes a first phase that is continuous and a second phase that is phase-separated from the first continuous phase
• the first continuous phase has a glass transition temperature of at least 4O 0 C and includes a first biodegradable polymer having chains (e g , a polylactide homopolymer or copolymer)
• the chains of the first biodegradable polymer are oriented along an axis
• the second phase has a glass transition temperature of 15 0 C or less and includes a second biodegradable polymer (e g , a polymer selected from the group consisting of poly(tnmethylene carbonate) (PTMC), polycaprolactone (PCL), polyhydroxybutyrate, and combinations thereof)
• a second biodegradable polymer e g , a polymer selected from the group consisting of poly(tnmethylene carbonate) (PTMC), polycaprolactone (PCL), polyhydroxybutyrate, and combinations thereof
• the modulus of the polymer blend parallel to the axis of orientation is at least 100% of the modulus of the first biodegradable polymer, and the strain at break of the polymer blend parallel to the axis of orientation is at least 120% of the strain at break of the first biodegradable polymer
• the modulus of the polymer blend parallel to the axis of orientation is at least 90% of the modulus of the first biodegradable polymer
• the strain at break of the polymer blend parallel to the axis of orientation is at least 120% of the strain at break of the first biodegradable polymer
• the polymer blend includes at least 5% by weight of the second phase, based on the total weight of the polymer blend
• the modulus of the polymer blend parallel to the axis of orientation is at least 80% of the modulus of the first biodegradable polymer
• the strain at break of the polymer blend parallel to the axis of o ⁇ entation is at least 120% of the strain at break of the first
• the modulus of the stretched and optionally quenched polymer blend parallel to the axis of stretching is at least 100% of the modulus of the first biodegradable polymer
• the strain at break of the stretched and optionally quenched polymer blend parallel to the axis of stretching is at least 120% of the strain at break of the first biodegradable polymer
• the modulus of the stretched and optionally quenched polymer blend parallel to the axis of stretching is at least 90% of the modulus of the first biodegradable polymer
• the strain at break of the stretched and optionally quenched polymer blend parallel to the axis of stretching is at least 120% of the strain at break of the first biodegradable polymer
• the polymer blend includes at least 5% by weight of the second phase, based on the total weight of the polymer blend
• the modulus of the stretched and optionally quenched polymer blend parallel to the axis of stretching is at least 80% of the modulus of the first biodegradable polymer
• the strain at break of the stretched and optionally quenched polymer blend parallel to the axis of stretching is at least 120% of the strain at break of the first biodegradable polymer
• the polymer blend includes at least 20% by weight of the second phase, based on the total weight of the polymer blend
• the medical devices and methods of making the disclosed devices can be advantageous m that for at least some embodiments, desirable combinations of properties can be obtained using readily available polymers that are commonly accepted as bemg suitable for use in medical devices Desirable combinations of properties can include biodegradability, rigidity (e g , modulus), strength (e g , ultimate tensile strength), toughness (e g , strain at break), and combinations thereof
• Figure 1 is a graphical representation showing Young's modulus (GPa, left y-axis, solid squares) and strain at break (%, right y-axis, open squares) for unstretched PLGA and each unstretched PLGA PTMC blend as a function of the weight fraction PTMC (x- axis)
• Figure 2 includes graphical representations of Young's modulus (GPa, left y-axis, solid squares) and strain at break (%, right y-axis, open squares) for PLGA and PLGA PTMC blends at various stretching (%) values parallel to stretching direction
• Figure 2A is for PLGA
• Figures 2B-2H are for PLGA PTMC blends having PTMC contents of 5 wt%, 10 wt%, 15 wt%, 20 wt%, 25 wt%, 30 wt%, and 40 wt%, respectively
• Figure 3 is a graphical representation mapping toughening and reinforcement observed for PLGA PTMC blends with various weight fractions of PTMC (y-axis) at various stretching (%) values (x-axis)
• the area enclosed withm the loop represents blends that have Young's modulus greater than 2 GPa and strain at break greater than 50% parallel to stretching direction
• the area outside the loop represents blends that have
• Figure 4 includes graphical representations of Young's modulus (solid squares, left y-axis) and strain at break (open squares, right y-axis) for PLGA and PLGA PTMC blends at various stretching (%) values perpendicular to stretching direction
• Figure 4A is for PLGA
• Figures 4B-4H are for PLGA PTMC blends having PTMC contents of 5 wt%, 10 wt%, 15 wt%, 20 wt%, 25 wt%, 30 wt%, and 40 wt%, respectively
• Figure 5 is a graphical representation mapping toughening and reinforcement observed for PLGA PTMC blends with various weight fractions PTMC (y-axis) at various stretching (%) values (x-axis)
• the area enclosed withm the upper loop represents blends that have Young's modulus greater than 2 GPa parallel to stretching direction, Young's modulus less than 1 7 GPa perpendicular to stretching direction, and strain at break greater than 50% in both directions
• the area enclosed withm the lower loop represents blends that have Young's modulus greater than 2 GPa parallel to stretching direction, Young's modulus greater than 1 7 GPa perpendicular to stretching direction, and strain at break greater than 50% m both directions
• Figures 6A and 6B include graphical representations of Young's modulus (GPa; solid symbols, left y-axis) and strain at break (open symbols, ⁇ ght y-axis) for various stretching (%) values parallel to stretching direction for 80 20 (wt wt) PLGA:PTMC blends
• Figure 6A shows various PTMC molecular weights (kg/mole, x-axis)
• Figure 6B shows various mixing times (minutes, x-axis)
• Figures 6C and 6D include graphical representations of Young's modulus (GPa, solid squares, left y-axis) and strain at break (%; open squares, right y-axis) at a stretching (%) value of 200% parallel to stretching direction for 85 15 (wt wt) PLDLLA PCL blends
• Figure 6C shows various stretching temperatures ( 0 C; x-axis)
• Figure 6D shows various stretching rates (mches/minute; x- axis)
• Figure 7 represents transmission electron micrographs showing microstructures of unstretched PLGA PTMC blends for various PTMC contents. Samples were stained with RuO 4 to show PTMC domains as dark areas. Figures 7A-7D are for 10 wt%, 20 wt%, 30 wt%, and 40 wt% PTMC, respectively Figure 8 illustrates a plot of wide angle X-ray scattering for an 80 20 (wt wt)
• the PTMC domains in a PLGA:PTMC (80 20) blend were discrete round particles dispersed m a PLGA continuous phase as illustrated in Figure 7B As shown m Figure 9, the PTMC domains in a PLGA PTMC (80 20) blend were stretched to shapes elongated in the stretching direction
• Figure 10 shows gel permeation chromatography (GPC) elution volume plots at various mixing times for fluorescent labeled PTMC PLGA blends.
• the eluting curve for pure fluorescent labeled PTMC was labeled as 0 minutes mixing time
• a second peak at lower elution volume was observed and increased as mixing time increased
• Figures 1 IA and 1 IB illustrate scanning electron micrographs for cross-sections of 80 20 (wt wt) PLGA:PTMC blends that were (A) solvent blended and (B) melt blended at 215 0 C. Voids were evident in the solvent blended sample but not in melt blended sample
• Figures 11C and 1 ID illustrate transmission electron micrographs of an 82 5 17 5 (wt wt) PLGA PTMC blend that was (C) cross-sectioned parallel to stretching, and (D) cross- sectioned perpendicular to stretching.
• Figure 12A is a graphical representation of molecular weight normalized to the initial molecular weight (y-axis) for an 82 5 17 5 (wt wt) PLGA PTMC blend as function of degradation time (days, x-axis) at various testing temperatures
• Figure 12B is a graphical representation of mass normalized to the initial values (y-axis) for an 82 5 17 5
• Figure 13A is a graphical illustration of a master degradation curve constructed by shifting degradation data (e.g., Figure 12A) obtained at various temperatures
• Figure 13B is a graphical illustration of the reciprocal of the logarithm of the shifting factors as a function of 1/(T-Tc). The linear relationship indicates that the degradation of the
• PLGA PTMC blend follows the time-temperature superposition principle.
• Figure 14A is a graphical representation of molecular weight normalized to the initial molecular weight (y-axis) for an 82.5.17.5 (wt.wt) PLGA.PTMC 100% stretched blend as function of degradation time (days, x-axis) at various testing temperatures
• Figure 14B is a graphical representation of mass normalized to the initial values (y-axis) for an 82 5 17 5 (wt:wt) PLGA PTMC 100% stretched blend as function of degradation time (days; x-axis) at various testing temperatures Testing temperatures were 37°C (stLGT37), 55°C (stLGT55), 7O 0 C (stLGT70), and 85 0 C (stLGT85).
• Figure 15 is a graphical illustration showing mechanical properties (y-axes) after various degradation times (weeks; x-axis) for an unstretched PLGA PTMC blend (circle) and a stretched PLGA:PTMC blend (square at the parallel direction and triangle at the perpendicular direction)
• Solid symbols indicate tensile modulus (pounds per square inch, PSI, left y-axis) and open symbols indicate strain at break (%, right y-axis)
• Figures 16A and 16B are graphical illustrations showing modulus (GPa; solid symbols, left y-axis) and strain at break (%; open symbols, right y-axis) of 85 15 (wt wt) PLA PCL (square), 85 15 (wt:wt) PLA:PTMC (diamond), and 80 20 (wt:wt) PLA:PTMC (triangle) blends (A) parallel to the stretching direction, and (B) perpendicular to the stretching direction, both as a function of stretching (%) value
• the present disclosure provides polymer blends and methods of making and using polymer blends that can have properties suitable for use in medical devices
• properties can include, for example, one or more of biodegradability, rigidity (e g , modulus), strength (e g , ultimate tensile strength), toughness (e g , strain at break), and combinations thereof.
• the present disclosure provides an implantable medical device that includes a polymer blend
• a polymer blend is intended to refer to at least two intimately mixed polymers that are typically homogeneous on the macroscopic level
• the polymer blend includes: a first phase that is continuous and a second phase that is phase-separated from the first continuous phase.
• phases of a polymer blend are intended to refer to domains that include materials (e.g., homopolymers, copolymers, and/or miscible mixtures of polymers) that are substantially homogeneous, and preferably homogeneous, on a microscopic level More specifically, the term “continuous phase” is intended to refer to a phase in which any point withm the phase can be reached by travelling from any other point within the phase without exiting the phase (i.e., the path travelled between the points is entirely within the phase).
• phase that is "phase-separated" from a continuous phase is intended to refer to a domain that has a physical boundary from the other phase or phases.
• the phase that is phase-separated can be a discrete phase or another continuous phase
• discrete phase is intended to refer to a phase that includes a plurality of non- connected domains of the same composition.
• the domains of the discrete phase can be symmetrical (e.g., spherical) or unsymmetrical (e.g , needle shaped)
• unsymmetrical domains of a phase-separated phase can be oriented in one or more directions.
• the phase-separated phase can be anisotropic and oriented along one axis (i.e., uniaxially oriented) to result in domains having an aspect ratio (i e., the maximum dimension of the phase divided by the minimum dimension of the phase) of at least 1 1
• the phase-separated phase can be oriented in two directions.
• the polymer blend typically includes at least 0.1% by weight of the second phase- separated phase, based on the total weight of the polymer blend, and in certain embodiments at least 0.5%, 1%, 2%, 3%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the second phase-separated phase, based on the total weight of the polymer blend.
• the first continuous phase includes a first biodegradable polymer (e.g., a polylactide homopolymer or copolymer)
• a first biodegradable polymer e.g., a polylactide homopolymer or copolymer
• biodegradable and bioerodible are used interchangeably and are intended to broadly encompass materials including, for example, those that tend to break down upon exposure to physiological environments.
• one or both of the first and second polymers are biodegradable polymers that can optionally biodegrade at sufficiently high rates to enable them to be considered for use in specific medical device applications
• the continuous phase that includes the first biodegradable polymer typically is capable of contributing to the mechanical stability of the device, especially at the upper temperature range at which the device may be made, implanted, and/or used (e g , 37°C and above)
• the continuous phase typically has a glass transition temperature of at least 40 0 C, and m certain embodiments at least 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, 47°C, 48°C, 49°C, 50 0 C, 55°C, or 60 0 C
• the first biodegradable polymer having chains included in the continuous phase can, for example, be an amorphous glassy material, which may be rigid and brittle below its glass transition temperature
• the term "rigid” means that the material has a modulus (E) of greater than 0 5 GPa at the temperature of interest
• the term “brittle” means that the mate ⁇ al has a strain at break (epsilon) of less than 10%
• exemplary polymers include, but are not limited to, polylactides (e g , homopolymers and/or copolymers)
• Polylactide homopolymers and copolymers include, for example, poly(L-lactide) (PLLA), poly(D,L-lactide) (PDLLA), poly(L-lactide-c ⁇ -D,L- lactide) (PLDLLA), poly(L-lactide-co-
• the chains of the first biodegradable polymer are oriented along an axis
• "oriented" is intended to refer to a non-isotropic chain orientation m which at least one of the assembly average chain projections at the X, Y, and/or Z directions is different than the remaining proj ection or proj ections
• the second phase of the polymer blend is phase-separated from the first continuous phase and is typically more flexible than the first continuous phase, especially at the lower temperature range at which the device may be made, implanted, and/or used (e g , 25°C and below)
• the phase-separated phase typically has a glass transition temperature of 15 0 C or less, and m certain embodiments 14 0 C or less, 13 0 C or less, 12 0 C or less, 11 0 C or less, 1O 0 C or less, 5°C or less, 0 0 C or less, -5 0 C or less, or -1O 0 C or less
• the second biodegradable polymer included in the second phase-separated phase can, for example, be an amorphous polymer that is rubbery above its glass transition temperature
• the term "rubbery" means that the material has a modulus (E) of less than 0 5 GPa at the temperature of interest
• the second modulus (E) of less than
• exemplary polymers include, but are not limited to, poly(t ⁇ methylene carbonate) (PTMC), polycaprolactone (PCL), polyhydroxybutyrate, polydioxane, and combinations thereof
• the modulus of the polymer blend parallel to the axis of orientation is at least 100% of the modulus of the first biodegradable polymer, and the strain at break of the polymer blend parallel to the axis of orientation is at least 120% of the strain at break of the first biodegradable polymer
• the modulus of the polymer blend parallel to the axis of orientation is at least 90% of the modulus of the first biodegradable polymer
• the strain at break of the polymer blend parallel to the axis of orientation is at least 120% of the strain at break of the first biodegradable polymer
• the polymer blend includes at least 5% by weight of the second phase, based on the total weight of the polymer blend
• the modulus of the polymer blend parallel to the axis of orientation is at least 80% of the modulus of the first biodegradable polymer
• the strain at break of the polymer blend parallel to the axis of orientation is at least 120% of the strain at break of the first biodegradable
• the modulus and strain at break parallel to the axis of orientation of a polymer blend film that has been stretched, and in certain embodiments quenched, can be determined by the following method Typically, the thickness of the film is 0 5 mm to 1 mm
• Microtensile bars ASTM D 1708
• ASTM D 1708 can be cut from the polymer blend film with a die cutter with the long axis of the microtensile bars being aligned parallel to the direction of stretching The microtensile bars can then be tested according to ASTM D 1708
• the modulus of the polymer blend parallel to the axis of orientation is typically at least 80%, 90%, 100%, 110%, or 125% of the modulus of the first biodegradable polymer
• the strain at break of the polymer blend parallel to the axis of orientation is typically at least 120%, 130%, 140%, 150%, 200%, 300%, 500%, 1000%, or 2000% of the strain at break of the first biodegradable polymer
• the modulus and strain at break of the polymer blend in a direction perpendicular to the axis of orientation can be different than the modulus and strain at break of the polymer blend parallel to the axis of orientation (i e , the polymer blend exhibits anisotropic properties)
• the modulus and strain at break of the polymer blend m at least one direction perpendicular to the axis of orientation can be sufficient for use m an implantable medical device
• the modulus and strain at break perpendicular to the axis of orientation of a polymer blend film that has been stretched, and in certain embodiments quenched can be determined by the following method Typically, the thickness of the film is 0 5 mm to 1 mm Microtensile bars (ASTM D 1708) can be cut from the polymer blend film with a die cutter with the long axis of the microtensile bars being aligned perpendicular to the direction of stretching The microtensile bars can then be tested according to ASTM D1708
• the modulus of the polymer blend in a direction perpendicular to the axis of orientation is typically at least 75%, 80%, 85%, 90%, 95%, or 100% of the modulus of the first biodegradable polymer
• the strain at break of the polymer blend m a direction perpendicular to the axis of orientation is typically at least 100%, 200%, 300%, 500%, 1000%, or 2000% of the strain at break of the first biodegradable polymer In addition
• the present disclosure provides a method of preparing an implantable medical device
• the method includes blending (e g , melt blending) components including a first biodegradable polymer having chains and a second biodegradable polymer under conditions effective to form a polymer blend
• the polymer blend includes a first phase that is continuous and a second phase that is phase-separated from the first continuous phase
• the first continuous phase has a glass transition temperature of at least 4O 0 C and includes the first biodegradable polymer
• the second phase has a glass transition temperature of 15°C or less and includes the second biodegradable polymer
• the method further includes stretching (e g , melt stretching) the polymer blend under conditions effective to orient the chains of the first biodegradable polymer along the axis of stretching, optionally quenching the stretched polymer blend, and forming a medical device from the stretched and optionally quenched polymer blend
• the modulus of the stretched and optionally quenched polymer blend parallel to the axis of stretching
• the modulus of the stretched and optionally quenched polymer blend parallel to the axis of stretching is at least 80% of the modulus of the first biodegradable polymer
• the strain at break of the stretched and optionally quenched polymer blend parallel to the axis of stretching is at least 120% of the strain at break of the first biodegradable polymer
• the polymer blend includes at least 20% by weight of the second phase, based on the total weight of the polymer blend
• one or more of the components that are melt blended can include, for example, one or more of a wide variety of additives, and particularly particulate additives, such as, for example, fillers (e g , including particulate, fiber, and/or platelet material), other polymers (e g , polymer particulate materials such as polytetrafluoroethylene can result in higher modulus), imaging particulate materials (e g , banum sulfate for visualizing material placement using, for
• melt blending is meant to include mixing at temperatures at which at least one component is melted and can flow under stress Melt blending can be carried out using a wide variety of methods including, for example, dispersing and/or distributing Mixing can be carried out using, for example, a simple shear machine, a Banbury mixer, a single or twin screw extruder, a helicone mixer, a multidirectional rotation mixer, or combinations thereof
• melt blending conditions effective to form a continuous phase including the first biodegradable polymer and a phase-separated-phase including the second biodegradable polymer will vary depending on the specific combination of biodegradable polymers selected for blending
• effective melt blending conditions will be apparent to one of skill in the art in view of the description and examples included m the present disclosure, m addition to melt blending conditions known in the art See, for example, Polymer Alloys and Blends Thermodynanics and Rheology, Utracki, Ed , Hanser Publishers, New York (1990)
• the first component includes one or more polylactide homopolymers and/or copolymers
• the second component includes one or more of poly(tnmethylene carbonate) (PTMC), polycaprolactone (PCL), polyhydroxybutyrate, and polydioxane
• melt blending conditions effective to form a continuous phase including the one or more polylactide homopolymers and/or copolymers, and a phase-separated phase including the one or more of poly(trimethylene carbonate) (PTMC), polycaprolactone (PCL), polyhydroxybutyrate, and polydioxane typically include a temperature of 6O 0 C to 250 0 C (and m certain embodiments 60 0 C to 23O 0 C), a mixing rate of 10 revolutions per mmute (pi) to 300 rpm (depending on the mixing device), for a time of 1 minute to 1 hour
• the conditions used for melt blending the first biodegradable polymer and the second biodegradable polymer can be effective to result in reactive blending
• reactive blending is used to refer to a method in which one or more new components are generated during mixing
• reactive blending of poly(methyl methacrylate) and bisphenol A polycarbonate can result in the formation of copolymers
• the conditions used for melt blending PLGA and PTMC can be effective to result in a trans-esterif ⁇ cation reaction that results in chain segment exchange between ester groups of the PLGA and carbonate groups of the PTMC Chain segment exchange can result in the formation of block copolymers PLGA PTMC Because the reaction may occur randomly within chains, the resulting copolymers may be random multiple block copolymers The in situ formation of such copolymers can be advantageous m that potentially difficult and/or expensive methods of separately preparing such copolymers (e g , as compatibilizers) can potentially be avoided
• the copolymer can have a preference for location at an interface between the domain including the first polymer and the domain including the second polymer Because such copolymers can have a preference for location at an interface between domains, the copolymer can act in a manner similar to a surfactant, for example, to increase mterfacial bond strength between domains and/or to reduce dispersed domain size, effects which can improve toughness of the blend
• the components including the first biodegradable polymer and the second biodegradable polymer can also be blended by solvent blending
• Solvent blending typically includes dissolving or dispersing each polymer m a solvent, then removing the solvent from the solution or dispersion of the polymers Typically the same solvent is used to dissolve or disperse each polymer to be blended Alternatively, different solvents may be used to dissolve or disperse each polymer Typically, each solvent is at least partially soluble m the other solvent Typically, solutions or dispersions include 0 1% to 99 9% by weight of each polymer
• solvents can be used including, for example, tetrahydrofuran (THF), chloroform, methylene chloride, and combinations thereof
• THF tetrahydrofuran
• chloroform chloroform
• methylene chloride and combinations thereof
• the solvents have sufficient volatility to allow for removal under reduced pressure
• the components including the first biodegradable polymer and the second biodegradable polymer (as described herein) can also be blended using supercritical carbon dioxide
• melt stretching is meant to include stretching a material at a temperature at or above the Tg of the material
• cold stretching is meant to include stretching a material at a temperature lower than the Tg of the material Stretching can be simultaneous with and/or subsequent to blending
• Stretching can be carried out using a wide variety of methods including, for example, uniaxial drawing, biaxial drawing, extrusion, injection molding, blow molding, blowing film, and combinations thereof
• Stretching conditions effective to orient the chains of the first biodegradable polymer along the axis of stretching typically include a stretching ratio of greater than 1 to 100, wherein the stretching ratio is defined as the length along an axis of stretching after stretching divided by the length along the same axis before stretching. Stretching can conveniently be reported as stretching (%), which is equal to 100 times the (stretching ratio - 1).
• Stretching is earned out at a rate selected to avoid breaking the sample Typically the stretching rate (stretching ratio per unit time) is at most 20 per minute, in some embodiments at most 10 per minute, and in certain embodiments at most 5 per mmute In certain embodiments, the stretching is carried out at a temperature that is at or above the Tg of at least one of the biodegradable polymers Typically, stretching is carried out at a temperature of room temperature (e.g , 25°C) or above In some embodiments stretching is carried out at a temperature of no greater than
• the stretched polymer blend can be quenched
• quenching is meant to include cooling the sample to a temperature at which chain orientation becomes locked or frozen
• quenching can assist in retention of the orientation along the axis of stretching of the chains of the first biodegradable polymer.
• Quenching can be carried out using a wide variety of methods including, for example, contact with fluids (gases or liquids), contact with solids, immersion in liquids, and combinations thereof
• Quenching conditions effective to retain the orientation along the axis of stretching of the chains of the first biodegradable polymer typically include a cooling rate high enough such that the degree of chain orientation does not substantially decrease due to relaxation Typical cooling rates include rates of 50°C/mmute to 100°C/second
• the first component includes one or more polylactide homopolymers and/or copolymers
• the second component includes one or more of poly(trimethylene carbonate) (PTMC), polycaprolactone (PCL), polyhydroxybutyrate, and polydioxane.
• melt stretching conditions effective to orient the discrete phase along the axis of stretching typically include a stretching ratio of 1 5 to 5, wherein the stretching ratio is defined as the length along an axis of stretching after stretching divided by the length along the same axis before stretching. Stretching can conveniently be reported as stretching (%), which is equal to 100 times the (stretching ratio - 1) Stretching is carried out at a rate selected to avoid breaking the sample
• the stretching rate is 1 1 per minute to 10 per mmute
• the stretching is carried out at a temperature that is at or above the Tg of at least one of the biodegradable polymers
• stretching is carried out at a temperature of 60 0 C to 100 0 C
• quenching conditions effective to retain at least a portion of the orientation of the discrete phase typically include cooling rates of 10°C/second to 100°C/second
• stretched and optionally quenched polymer blends can form a medical device without further processing
• the stretched and optionally quenched polymer blends, as prepared can be in the form of a stent
• additional processing steps may optionally be used to form a medical device
• the stretched and optionally quenched polymer blend can be extruded or blow molded to form medical devices such as, for example, stents
• the stretched and optionally quenched polymer blends can be shaped to form a medical device, preferably a biodegradable medical device
• the stretched and optionally quenched polymer blends can be shaped by methods known in the art including compression molding, injection molding, casting, extruding, milling, blow molding, or combinations thereof
• a "medical device” includes devices that have surfaces that contact tissue, bone, blood, or other bodily fluids in the course of their operation, which fluids are subsequently used in patients This can include, for example, extracorporeal devices for use m surgery such as blood oxygenators, blood pumps, blood sensors, tubing used to carry blood, and the like which contact blood which is then returned to the patient
• endoprostheses implanted in blood contact in a human or animal body such as vascular grafts, stents, pacemaker leads, heart valves, and the like, that are implanted m blood vessels or m the heart
• devices for example, extracorporeal devices for use m surgery such as blood oxygen
• stretched and optionally quenched polymer blends have physical properties (e g , mechanical properties) that are useful for certain medical devices.
• physical properties e g , mechanical properties
• the sheets were cut into rectangular pieces (5 cm x 3 8 cm) Some samples were used directly for mechanical testing of unstretched samples Other samples were loaded in a tensile testing instrument (MTS, MN) The grips and samples were housed with a heating chamber and heated for 10 minutes to reach equilibrium at 75 0 C The gage length between the two grips was set at 2 5 cm and loaded samples were stretched at a rate of 25 4 cm/mm to the desired stretching ratio The samples were then immediately quenched by immersion in water or by contact with water soaked paper to provide the stretched and quenched samples Micro-tensile bars (ASTM D 1708) were cut from the stretched and quenched sheets with a die cutter at directions both parallel and perpendicular to the stretching direction Tensile tests were performed at room temperature at a cross head rate of 2 54 cm/mm with an MTS tensile instrument Yielding points were determined as 2% strain after the maximum modulus Morphologies of microstructures of blend samples were evaluated with both scanning electron microscopy (SEM, Jeol 5900
• Cham orientation was evaluated with X-ray scattering tests
• Data were acquired using an area detector, with a two-theta range of 30°, centered at two-theta values of 0° and 30°, and exposure times of 60 seconds
• Figure 3 is a graphical representation mapping toughening and reinforcement observed for PLGA PTMC blends with various weight fractions PTMC (y-axis) at various stretching (%) values (x-axis)
• Figure 4 includes graphical representations of Young's modulus (GPa, left y-axis, solid squares) and strain at break (%, right y-axis, open squares) for PLGA and PLGA PTMC blends at various stretching (%) values perpendicular to stretching direction
• Figure 4A is for PLGA
• Figures 4B-4H are for PLGA PTMC blends having PTMC contents of 5 wt%, 10 wt%, 15 wt%, 20 wt%,
• FIG. 5 is a graphical representation mapping toughening and reinforcement observed for PLGA PTMC blends with various weight fractions PTMC (y-axis) at various stretching (%) values (x-axis)
• the area enclosed withm the upper loop represents blends that have Young's modulus greater than 2 GPa at the direction parallel to stretching, Young's modulus less than 1 7 GPa at a direction perpendicular to stretching, and strain at break greater than 50% m both directions
• the area enclosed withm the lower loop represents blends that have Young's modulus greater than 2 GPa parallel to stretching direction, Young's modulus greater than 1 7 GPa perpendicular to stretching direction, and strain at break greater than 50% in both directions
• the dot in the lower loop represents a blend having a Young's modulus of 2 2 GPa and a strain at break of 128% parallel to stretching direction, and a Young's modulus of 1 8 GPa and a strain at
• Figure 6 Figures 6A and 6B include graphical representations of Young's modulus (GPa, solid symbols, left y-axis) and strain at break (%, open symbols, right y-axis) for various stretching (%) values parallel to stretching direction for 80 20 (wt wt) PLGA PTMC blends
• Figure 6A shows various PTMC molecular weights (kg/mole, x-axis)
• Figure 6B shows various mixing times (minutes, x-axis)
• Figures 6C and 6D include graphical representations of Young's modulus (GPa, left y-axis, solid squares) and strain at break (%, right y-axis, open squares) at a stretching (%) value of 200% parallel to stretching direction for 85 15
• a PLDLLA PCL blend stretched for 200% had a 3 1 GPa modulus if cooled with water (rapid cooling) If cooled with air (slower cooling), the modulus was 1 8 GPa
• Figure 7 illustrates transmission electron micrographs showing microstructures of unstretched PLGA PTMC blends for various PTMC contents Samples were stained with
• Figures 7A-7D are for 10 wt%, 20 wt%, 30 wt%, and 40 wt% PTMC, respectively At low PTMC contents (e g , 10 wt%), the PTMC domain was present as a discrete phase At higher PTMC contents (e g , 40 wt%), the PTMC phase and the PLGA phase approached co-contmuity After the blends were stretched, there were two changes The first change was chain orientation as evidenced from the wide angle X-ray scattering
• Figure 8 illustrates a plot of wide angle X-ray scattering for an 80 20 (wt wt) PLGA PTMC blend for various stretching (%) values
• the X-ray beam is perpendicular to the stretching direction
• An amorphous blend (before stretching) has a dispersive scattering nng As the stretching (%) increased, a few scattering spots appeared The white spots for stretching (%) greater than 100% indicated chain orientation
• a fluorescent active compound (9-anthracenemethanol) was used to initiate a low molecular weight (approximately 12 kg/mole) PTMC sample to give a labeled PTMC that can be detected by a fluorescent detector used with high pressure liquid chromatography (HPLC)
• HPLC high pressure liquid chromatography
• the labeled PTMC was blended with a PLGA sample (LG857, Bl, approximately 600 kg/mole) m a ratio of PLGA:PTMC of 80:20 (wt wt).
• the blend was analyzed with gel permeation chromatography (GPC).
• Figure 10 shows gel permeation chromatography (GPC) elution volume curves of fluorescent labeled PTMC-PLGA blends mixed for various times.
• the elutmg curve for pure fluorescent labeled PTMC was labeled as 0 minutes mixing time
• a second peak at lower elution volume, higher molecular weight was observed and increased as mixing time increased
• new materials e g , PTMC PLGA copolymers
• FIGS 11C and 1 ID illustrate transmission electron micrographs of an 82 5 17 5 (wt wt) PLGA PTMC blend that was (C) cross-sectioned parallel to stretching, and (D) cross-sectioned perpendicular to stretching
• Higher bond strength between phases in the melt blended sample could be attributed, for example, to the formation of new materials (e g , PTMC PLGA copolymers) through trans-esterif ⁇ cation reactions, for example Notably, trans-esterification reactions would not be expected to readily occur m samples that were solvent blended at low temperatures
• Disc samples were placed m PBS solution (pH7 4) and incubated at 37 0 C for various times. The degradation media was refreshed as needed to keep the pH unchanged.
• Figure 12A is a graphical representation of molecular weight normalized to the initial molecular weight (y-axis) for an 82.5 17 5 (wt:wt) PLGA PTMC blend as a function of degradation time (days; x-axis) at various testing temperatures
• Figure 12B is a graphical representation of mass normalized to the initial values (y-axis) for an 82 5:17.5 (wt:wt) PLGA PTMC blend as function of degradation time (days; x-axis) at various testing temperatures Testing temperatures were 37 0 C (LGT37), 55 0 C (LGT55), 70 0 C (LGT70), and 85°C (LGT85) Degradation at higher temperatures was faster as indicated by the faster changes in measure M n and mass
• Figure 13A is a graphical illustration of a master degradation curve constructed by shifting degradation data (e.g., Figure 12A) obtained at various temperatures
• shifting degradation data e.g., Figure 12A
• aT logarithm of the shifting factors
• Equation 1 can be rearranged into the following linear form 1 1 - C 2
• FIG. 15 is a graphical illustration showing mechanical properties (y-axes) after various degradation times (weeks, x-axis) for an unstretched PLGA PTMC blends

Landscapes

• Health & Medical Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Dermatology (AREA)
• Heart & Thoracic Surgery (AREA)
• Surgery (AREA)
• Vascular Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Transplantation (AREA)
• Materials For Medical Uses (AREA)
• Biological Depolymerization Polymers (AREA)
• Compositions Of Macromolecular Compounds (AREA)
• Prostheses (AREA)

Priority Applications (4)

Applications Claiming Priority (4)

Publications (2)

Family

ID=41340992

Family Applications (1)

Country Status (6)

Families Citing this family (6)

Citations (1)

Family Cites Families (28)

• 2009
  • 2009-08-03 US US12/534,264 patent/US8129477B1/en active Active
  • 2009-08-04 CN CN200980135834.0A patent/CN102143766B/zh active Active
  • 2009-08-04 WO PCT/US2009/052626 patent/WO2010017153A2/en not_active Ceased
  • 2009-08-04 JP JP2011522153A patent/JP2011530331A/ja active Pending
  • 2009-08-04 ES ES09791121T patent/ES2704014T3/es active Active
  • 2009-08-04 EP EP09791121.8A patent/EP2318059B1/en active Active

Patent Citations (1)

Also Published As

Similar Documents

Legal Events